FDA
-
-
-
-
-
-
-
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
-
-
-
-
-
-
-
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
-
-
-
-
-
-
-
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2b CORAL Trial
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Trevi Therapeutics (TRVI)
-
-
-
-
-
-
-
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

